-
1 Comment
CKD Bio Corp is currently in a long term downtrend where the price is trading 3.8% below its 200 day moving average.
From a valuation standpoint, the stock is 72.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.4.
CKD Bio Corp's total revenue sank by 29.4% to $27B since the same quarter in the previous year.
Its net income has dropped by 128.4% to $-987M since the same quarter in the previous year.
Finally, its free cash flow grew by 45.1% to $-6B since the same quarter in the previous year.
Based on the above factors, CKD Bio Corp gets an overall score of 2/5.
| ISIN | KR7063160006 |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | KO |
| CurrencyCode | KRW |
| Sector | Healthcare |
| Market Cap | 121B |
|---|---|
| PE Ratio | None |
| Target Price | 27000 |
| Dividend Yield | 0.4% |
| Beta | 1.45 |
CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also exports its products. The company was founded in 1941 and is headquartered in Seoul, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 063160.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
